Sou Hu Cai Jing·2026-02-27 09:44Core Viewpoint - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has received approval from the China Securities Regulatory Commission to publicly issue technology innovation corporate bonds totaling up to RMB 6 billion, which is valid for 24 months from the date of approval [1] Group 1: Stock Performance - As of the market close on February 27, 2026, the stock price of Fosun Pharmaceutical was CNY 26.48, down 0.11% from the previous trading day [1] - The stock opened at CNY 26.51, reached a high of CNY 26.6, and a low of CNY 26.42, with a trading volume of CNY 334 million and a turnover rate of 0.6% [1] Group 2: Bond Issuance - The company plans to issue the bonds in phases based on funding needs and market conditions, while fulfilling relevant information disclosure obligations [1]